+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006)



Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006)



Cancer 118(20): 5050-5059



Patients with osteosarcoma and Ewing sarcoma have achieved longer survival over the past decades, but late side effects of chemotherapy and radiotherapy have become important concerns. The authors reviewed all patients with localized osteosarcoma or Ewing sarcoma who had been enrolled in the Italian Sarcoma Group neoadjuvant protocols from 1983 through 2006. Data were updated in December 2010 to determine 3 endpoints: the incidence of a secondary primary cancer (designated as "second malignant neoplasm" [SMN]), infertility, and cardiotoxicity. Data were available on 883 patients with osteosarcoma and 543 patients with Ewing sarcoma. In the osteosarcoma group, there were 39 SMNs (4.4%) in 36 patients; in the Ewing sarcoma group, 15 patients (2.8%) experienced a single SMN each. The cumulative 10-year and 20-year incidence of an SMN (±standard error) was 4.9% ± 0.9% and 6.1% ± 1.2%, respectively, in the osteosarcoma group and 3.4% ± 0.9% and 4.7% ± 1.6%, respectively, in the Ewing sarcoma group. The most common SMN in the osteosarcoma group was breast cancer (n = 11), and the most common SMN in the Ewing sarcoma group was radiotherapy-induced osteosarcoma (n = 6). After 20 years, the risk of developing an SMN increased, whereas the risk of a recurrence of the primary tumor decreased. Permanent sterility was more common in males than in females. Doxorubicin cardiotoxicity occurred in 18 patients with osteosarcoma (2%) and in 7 patients with Ewing sarcoma (1.3%). The awareness of late side effects in long-term survivors of primary bone cancers should encourage longer follow-up.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054084310

Download citation: RISBibTeXText

PMID: 22415578

DOI: 10.1002/cncr.27493


Related references

Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Annals of Oncology 22(5): 1221-1227, 2011

Unusual sites of Ewing sarcoma (ES): a retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG). European Journal of Cancer 49(17): 3658-3665, 2013

Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Annals of Oncology 23(11): 2970-2976, 2012

Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience. Acta Orthopaedica Scandinavica. Supplementum 285: 69-73, 1999

Health status at long-term follow-up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: a Scandinavian sarcoma group study. Pediatric Blood and Cancer 53(1): 84-89, 2009

Ewing's sarcoma and primitive neuroectodermal tumor of hand and forearm. Experience of the Cooperative Ewing's Sarcoma Study Group. Journal of Cancer Research and Clinical Oncology 131(4): 219-225, 2005

Neoadjuvant chemotherapy of sarcoma. The experiences of the German Society for Pediatric Oncology studies on osteosarcoma, Ewing's sarcoma and rhabdomyosarcoma. Deutsche Medizinische Wochenschrift 112(36): 1385-1390, 1987

Improved Prognosis for Patients with Ewing Sarcoma in the Sacrum Compared with the Innominate Bones: The Scandinavian Sarcoma Group Experience. Journal of Bone and Joint Surgery. American Volume 98(3): 199-210, 2016

Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. Pediatric Blood and Cancer 64(12):, 2017

Mediastinal mass following chemotherapy in patients with Ewing sarcoma and osteosarcoma. Journal Of Internal Medicine. 239(5): 457-460, 1996

The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. European Journal of Cancer 33(3): 357-361, 1997

Ultrasonographic monitoring of the effects of preoperative chemotherapy in osteosarcoma and Ewing's sarcoma. International Orthopaedics 19(5): 312-314, 1995

Demographic Analysis of Patients with Osteosarcoma, Chonddrosarcoma, Ewing's Sarcoma from one Sarcoma Center in Switzerland. Praxis 104(13): 673-680, 2015

Late effects of therapy in adult survivors of osteosarcoma and Ewing's sarcoma. Medical and Pediatric Oncology 20(1): 6, 1992

Chemotherapy in Ewing's sarcomaThe Scandinavian Sarcoma Group experience. Acta Orthopaedica 75(Sup311): 87-91, 2004